Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 18,392 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Female Clear all
Active, not recruiting Phase 2 Interventional

9-ING-41 in Patients With Advanced Cancers

NCT03678883
View directory record Official record
Conditions
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
Interventions
9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan
Drug
Lead sponsor
Actuate Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 21, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Relationships Between Exercise and Appetite in Women With Loss of Control Eating

NCT06602973
View directory record Official record
Conditions
Eating Disorders, Binge-Eating Disorder, Bulimia Nervosa
Interventions
Rest, Fed Exercise, Fasted Exercise
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 21, 2026, 5:23 PM EDT
Terminated Phase 1 Interventional

Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma

NCT01144169
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Hydroxychloroquine (HC)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
19 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 21, 2026, 5:23 PM EDT
Terminated Phase 1 Interventional

RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer

NCT01208441
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
letrozole, gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery, breast biopsy, diagnostic laboratory biomarker analysis, pharmacological study
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 21, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

PICO Negative Pressure Wound Therapy in Obese Women Undergoing Elective Cesarean Delivery.

NCT03414762
View directory record Official record
Conditions
Cesarean Section Complications, Cesarean Wound; Dehiscence, Cesarean Wound Disruption
Interventions
PICO Negative Pressure Wound Therapy, Standard Dressing
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 21, 2026, 5:23 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

ANXA5 M2 Haplotyping in IVF Patients and Embryos

NCT04544462
View directory record Official record
Conditions
Infertility, Miscarriage, Recurrent, Pregnancy Complications
Interventions
M2 Test
Other
Lead sponsor
Genomic Prediction Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
North Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 21, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

NCT00793546
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Bosutinib, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Lake Worth, Florida • Joliet, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Oct 21, 2026, 5:23 PM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Platelet Rich Plasma Uterine Infusion

NCT06621342
View directory record Official record
Conditions
Infertility, Endometriosis
Interventions
PRP Experimental
Biological
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
23 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 21, 2026, 5:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Natural History of HPV From Infection to Neoplasia in Adolescents and Young Women

NCT01366742
View directory record Official record
Conditions
Human Papillomavirus, CIN 2, CIN 3
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 22 Years · Female only
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1987 – 2016
U.S. locations
2
States / cities
San Francisco, California • San Leandro, California
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 21, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Non-Invasive Neurally Adjusted Ventilatory Assist (NAVA) Prone vs Supine in Premature Infants

NCT05968586
View directory record Official record
Conditions
Neonatal Oxygen Desaturation, Premature, Ventilator Lung; Newborn, Apnea of Prematurity
Interventions
Body positioning
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
1 Minute to 3 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 21, 2026, 5:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina

NCT00194324
View directory record Official record
Conditions
Health, Vulvovaginal Candidiasis
Interventions
Miconazole nitrate, Magnetic resonance imaging, Moderate levels of exercise
Drug · Procedure · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2011 · Synced Oct 21, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

Effects of Caffeine on Intermittent Hypoxia in Infants Born Preterm

NCT01875159
View directory record Official record
Conditions
Hypoxia
Interventions
Caffeine citrate 6 mg/kg/day
Drug
Lead sponsor
American SIDS Institute
Other
Eligibility
33 Weeks to 37 Weeks
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 21, 2026, 5:23 PM EDT
Completed Phase 4 Interventional

Lidocaine for Pain After Urodynamic Testing

NCT03390790
View directory record Official record
Conditions
Voiding Disorders, Overactive Bladder, Urinary Incontinence
Interventions
Lidocaine gel 2%, Standard lubricant gel
Drug · Other
Lead sponsor
Atlantic Health System
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 21, 2026, 5:23 PM EDT
Completed Phase 2 Interventional

Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer

NCT00059813
View directory record Official record
Conditions
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
recombinant interferon alfa, oblimersen sodium, pharmacological study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2013 · Synced Oct 21, 2026, 5:23 PM EDT
Completed Phase 1 Interventional

An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery

NCT03011320
View directory record Official record
Conditions
Ovary Cancer
Interventions
EC1456, 99mTc-Etarfolatide
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Concord, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 21, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Results available

A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

NCT02133742
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Axitinib, MK-3475
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
19
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 21, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Trial of Bed Versus Stirrups Delivery in Nulliparous Women for Prevention of Perineal Lacerations

NCT00895973
View directory record Official record
Conditions
Perineal Lacerations
Interventions
Stirrups delivery vs bed delivery
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
16 Years and older · Female only
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 21, 2026, 5:23 PM EDT
Terminated Not applicable Interventional Results available

Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer

NCT04779489
View directory record Official record
Conditions
Bladder Cancer
Interventions
personalized ultrafractionated stereotactic ablative radiotherapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 21, 2026, 5:23 PM EDT
Completed No phase listed Observational

Prediction of Impaired Survival in Elderly Bladder Cancer Patients Opting for Radical Cystectomy

NCT02039310
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
65 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 21, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers

NCT01947920
View directory record Official record
Conditions
Healthy
Interventions
Tramadol HCl, 50 mg, Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Oct 21, 2026, 5:23 PM EDT
Withdrawn Phase 3 Interventional

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

NCT02015780
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Fasiglifam, Placebo, Antihyperglycemic therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 21, 2026, 5:23 PM EDT
Completed Phase 2 Interventional

Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors

NCT00070096
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
ixabepilone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 21, 2026, 5:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Transthoracic Echocardiography of Ventricular Function of Parturients in Labor

NCT04481503
View directory record Official record
Conditions
Obstetric Labor Complications, Cardiovascular Diseases in Pregnancy, Cardiovascular Risk Factor
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 21, 2026, 5:23 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants

NCT02620761
View directory record Official record
Conditions
Patent Ductus Arteriosus (PDA), Acute Kidney Injury (AKI)
Interventions
Fenoldopam, 0.9%NS
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
0 Days to 28 Days
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 21, 2026, 5:23 PM EDT